Triventures is a venture capital firm founded in 2010, with its headquarters in Herzliya, Israel, and an additional office in Menlo Park, California. The firm specializes in incubation, seed, and early to mid-stage investments, primarily focusing on the medical device sector. Triventures targets innovations in medical device technology, digital medicine, and healthcare-related technologies, alongside non-health sectors such as insurtech, fintech for healthcare, e-commerce, and cybersecurity for healthcare. The firm emphasizes investing in startups led by exceptional entrepreneurs and seeks to identify cross-industry breakthroughs that leverage advanced technologies, including big data, artificial intelligence, and machine learning. With a team composed of industry leaders in healthcare and entrepreneurship, Triventures aims to foster advancements that improve health outcomes and drive technological progress across various sectors.
BioProtect Ltd. is an international medical device startup. It is primarily engaged in to the business of developing and commercializing biodegradable balloon spacers for the protection of normal tissue during cancer radiation therapy. The company's current focus in the growing radiotherapy spacers market, where its ProSpace balloon spacer (CE marked) has shown superior efficacy and safety in protecting the rectum during radiation therapy for prostate cancer. The company's technology platform of biodegradable implantable balloons suits a wide range of applications for unmet clinical needs. BioProtect was founded in the year 2004 and headquartered in Israel, with subsidiaries in Germany and US.
FeelBetter
Venture Round in 2023
FeelBetter is a healthcare optimization platform for value-based models identifying at-risk patients and interventions. The company was founded in 2018 and is based in Tel Aviv, Israel.
FEMSelect
Series B in 2022
FEMSelect is making a lasting impact on women's health by delivering an innovative technology platform. It is the developer of EnPlace, a minimally invasive and mesh-free system for pelvic floor ligament fixation. Using EnPlace takes approximately 30 minutes. The patented delivery system enables the precise guidance, insertion, and deployment of the anchor unit. The anchor is designed to be introduced through the vaginal wall and secured to the pelvic floor ligament to provide stabilization. FEMSelect was founded in 2012 and is headquartered in Modi’in, Israel.
V-Wave
Series C in 2021
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.
EyeYon Medical
Series C in 2021
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.
Genoox
Series B in 2021
Genoox, Ltd. is a company that develops a cloud-based platform for managing and analyzing genomic data. Founded in 2014, the company aims to create a comprehensive network of real-world genomic and clinical data to enhance genetic diagnostics and personalized treatments. The platform connects clinicians, genetic counselors, and healthcare organizations, allowing them to share insights and make significant discoveries using advanced genomic tools and applications. By leveraging artificial intelligence and machine learning, Genoox's platform translates complex genetic data into actionable clinical information, helping healthcare providers to analyze rare genetic mutations and improve patient outcomes with increased accuracy and efficiency. The company is headquartered in Israel and serves over 1,700 health organizations across 44 markets worldwide.
V-Wave
Series C in 2020
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.
Genoox
Series B in 2018
Genoox, Ltd. is a company that develops a cloud-based platform for managing and analyzing genomic data. Founded in 2014, the company aims to create a comprehensive network of real-world genomic and clinical data to enhance genetic diagnostics and personalized treatments. The platform connects clinicians, genetic counselors, and healthcare organizations, allowing them to share insights and make significant discoveries using advanced genomic tools and applications. By leveraging artificial intelligence and machine learning, Genoox's platform translates complex genetic data into actionable clinical information, helping healthcare providers to analyze rare genetic mutations and improve patient outcomes with increased accuracy and efficiency. The company is headquartered in Israel and serves over 1,700 health organizations across 44 markets worldwide.
V-Wave
Series C in 2018
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.
CathWorks
Series B in 2017
CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, the company has developed the CathWorks FFRangio, a non-invasive device that provides objective, multi-vessel physiologic measurements. This tool transforms coronary angiography from a subjective visual assessment into an objective decision-making framework based on fractional flow reserve (FFR) metrics. By utilizing sophisticated algorithms to process visual information, CathWorks aims to improve the efficiency of cath lab operations and support healthcare providers in making data-driven clinical decisions.
Colospan
Venture Round in 2017
Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, that specializes in developing innovative solutions for colorectal surgeries. Founded in 2010, the company has created proprietary technology aimed at preventing anastomotic leaks and minimizing the need for diverting colonic stomas. Its lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site after procedures such as colectomy, which is often necessary in cases of severe intestinal inflammatory diseases and bowel or rectal cancer. By addressing the risk of leakage that can lead to prolonged hospitalization or additional surgeries, Colospan's devices aim to improve patient outcomes and facilitate a smoother recovery process while mitigating post-operative complications.
Colospan
Series B in 2017
Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, that specializes in developing innovative solutions for colorectal surgeries. Founded in 2010, the company has created proprietary technology aimed at preventing anastomotic leaks and minimizing the need for diverting colonic stomas. Its lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site after procedures such as colectomy, which is often necessary in cases of severe intestinal inflammatory diseases and bowel or rectal cancer. By addressing the risk of leakage that can lead to prolonged hospitalization or additional surgeries, Colospan's devices aim to improve patient outcomes and facilitate a smoother recovery process while mitigating post-operative complications.
EyeYon Medical
Venture Round in 2017
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.
V-Wave
Series B in 2016
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.
OrthoSpace
Venture Round in 2015
OrthoSpace Ltd. is an Israeli company specializing in the development and commercialization of biodegradable balloon systems designed to treat rotator cuff syndrome. Founded in 2009 and based in Caesarea, the company focuses on creating innovative solutions that aim to alleviate pain and enhance patients' range of motion while preserving their bone and joint structures. Its flagship product, InSpace™, has received the CE mark and is marketed in Europe, providing a non-invasive option for patients suffering from rotator cuff injuries. The balloon system mimics the function of the original bursa, acting as a spacer between the acromion and the humeral head to facilitate smooth movement and reduce friction during shoulder motion. As of 2019, OrthoSpace operates as a subsidiary of Stryker Corporation.
EyeYon Medical
Venture Round in 2015
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.